Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Clinical themes
- Scientific themes
-
3. Neuroinflammation in ALS: cause or consequence?
- Prof. Philip Van Damme
-
6. SOD1-related ALS: what has it told us about motor neuron degeneration? - part 1
- Prof. Dame Pamela Shaw
-
7. SOD1-related ALS: what has it told us about motor neuron degeneration? - part 2
- Prof. Dame Pamela Shaw
-
8. Expanding roles of RNA-binding proteins in neurodegenerative diseases
- Prof. Aaron D. Gitler
-
9. Oxidative stress in amyotrophic lateral sclerosis (ALS) 1
- Prof. Dame Pamela Shaw
-
10. Oxidative stress in amyotrophic lateral sclerosis (ALS) 2
- Prof. Dame Pamela Shaw
Printable Handouts
Navigable Slide Index
- Introduction
- Mutations in FUS lead to autosomal dominant ALS
- Mutations in FUS lead to juvenile, rapidly progressive ALS
- Mutations in FUS cluster in the C-terminal NLS part
- Mutations in FUS lead to impaired nuclear import
- Outstanding questions: how do FUS mutations lead to ALS?
- The Dormann & Haass working model
- Testing the Dormann & Haass working model: homologous recombination
- Testing the Dormann & Haass working model: Fus gene
- Testing the Dormann & Haass working model: Fus expression
- Testing the Dormann & Haass working model: knockout mice
- Testing the Dormann & Haass working model: gain of function in motor neurons
- Are Fus mutations in motor neurons toxic? (1)
- Are Fus mutations in motor neurons toxic? (2)
- Fus mutation has detrimental effect on motor neurons
- Motor phenotype in Fus∆NLS/+ knock-in mice: inverted grid test
- Motor phenotype in Fus∆NLS/+ knock-in mice
- Muscle defects in Fus knock-in mice
- Muscle defects in Fus knock-in mice is expressed in the muscle
- FUS controls post-synaptic gene expression
- iPS derived myotubes of FUS-ALS patients show similar alterations of AchR
- Fus pathway in the subsynaptic nuclei
- Outstanding questions: is FUS also involved in FTD?
- FUS inclusions in FTD
- Transcriptional effects of FUS in the CNS?
- Systems biology identifies co-regulated genes in the cortex of Fus∆NLS/+ mice
- mRNA processing genes are upregulated in the cortex of Fus∆NLS/+ mice
- Synaptic genes are downregulated in the cortex of Fus∆NLS/+ mice
- Ultrastructural alterations of inhibitory synapses in the cortex of Fus∆NLS/+ mice
- Abnormal synaptic physiology translates into abnormal behavior: activity
- Abnormal synaptic physiology translates into abnormal social behavior
- FUS mislocalization leads to cortical hyperexcitability and social defects
- Outstanding questions: can we therapeutically target FUS mutations?
- FUS autoregulation
- Hijacking FUS autoregulation: generation of genotypes of interest
- Hijacking FUS autoregulation: testing on the inverted grid
- Hijacking FUS autoregulation: immunohistochemistry
- Hijacking FUS autoregulation: intron expression
- FUS autoregulation: adding extra copy of WT FUS
- Take-home messages
- Acknowledgements
Topics Covered
- How do FUS mutations lead to ALS?
- Is FUS also involved in FTD?
- Can we therapeutically target FUS mutations?
- The Dormann & Haass working model
- FUS autoregulation
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Dupuis, L. (2023, December 31). Mechanisms of juvenile forms of ALS caused by FUS mutations [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 26, 2024, from https://doi.org/10.69645/QFQR8221.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Luc Dupuis has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Neuroscience
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome to the talk on
FUS mutations and how
FUS mutations participate in
juvenile forms of Amyotrophic
Lateral Sclerosis, ALS.
I'm Dr. Luc Dupuis Ph.D.,
I'm a research director
at Inserm in France,
at the University of Strasbourg.
0:21
What is the basis of the
association between FUS and ALS?
This comes from a 2009 paper
in Science by Caroline
Vance and colleagues
in which they found an
association between
mutations in the gene
coding FUS and ALS.
These are familial cases of
ALS with autosomal
dominant inheritance,
and you can see, for instance,
that all the black symbols
are affected individuals.
You can appreciate how over
several generations the gene
mutation co-segregates
with the disease
and is consistent with
the pattern of
autosomal inheritance.
FUS mutations are
almost 100% penetrant,
and they lead to a
juvenile form of ALS,
with some cases that begin
across the teenage years.
1:21
The two patterns of FUS
mutations are the following.
FUS mutations share
two features;
the first one is
illustrated on the left.
It's an early onset.
The median age at onset for
FUS patients is in one's '40s,
and most of the
ALS patients with
the FUS mutation have symptoms
of ALS before 50 years of age.
This is 10 to 25 years
younger than other ALS genes.
There are cases with people
younger than 25 years of age,
including teenage cases.
The second characteristic of
FUS mutation is the
fast progression.
About half of the FUS
ALS cases progress very
fast with early onset and
death within 12 months.